MLAB
Mesa Laboratorie (MLAB)
NASDAQ
$95.05+$0.10 (+0.10%)
Price as of Jul 14, 2026 4:16 AM EDT
  • $527.0M
    Market Cap
  • 15.47%
    1-Year Change
  • Scientific & Technical Instruments
    Industry

Key Performance

More
  • Earnings Score: 44
  • Momentum Score: 54
  • True Yield: N/A
  • Financial Health Score: 48
TradeSmith Loading

Latest Research & News

Why Mesa Laboratories Stock Is Getting Hit With a Huge Sell-Off Today

Mesa Laboratories stock plummeted 19.5% on May 27, 2026, after reporting Q4 fiscal 2026 results. While the company beat expectations on adjusted operating income per share ($3.30 vs. $1.54 estimate), sales of $63.72 million fell short of Wall Street expectations by approximately $1.48 million. CEO Siddhartha Kadia is conducting an internal review and will provide full-year guidance with the Q2 report.

05/27/2026, 3:36 PM • The Motley Fool

MESA LABS DECLARES QUARTERLY DIVIDEND

Mesa Laboratories announced a quarterly dividend of $0.16 per share, payable on September 15, 2025, to shareholders of record as of August 29, 2025.

07/03/2025, 12:00 PM • GlobeNewswire

Peers

Statistics

More
Day Range
$94.67
$97.96
$94.95
1-Year Range
$57.44
$109.13
$94.95
Latest Close$94.95
Change
-$0.66 (-0.70%)
Volume164,638
Market Cap$527.0M
Shares Outstanding5.5M
P/E (TTM)79.27
Diluted EPS (TTM)$1.21
Enterprise Value$651.6M

Information as of 07/13/2026

Company Profile

MESA LABORATORIES INC
MESA LABORATORIES INC
https://www.mesalabs.com
$527.0M
Market Cap
$6.7M
Net Income
Sector: Technology
Industry: Scientific & Technical Instruments
12100 West Sixth Avenue, Lakewood, CO, United States, 80228
303 987 8000

Mesa Laboratories, Inc. develops, designs, manufactures, sells, and services life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. The Sterilization and Disinfection Control segment offers biological, chemical, and cleaning indicators, used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes in the pharmaceutical, medical device, and healthcare industries. This segment also provides sterility assurance testing and laboratory services to the dental and pharmaceutical industries. The Biopharmaceutical Development segment develops, manufactures, sells, and services automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Clinical Genomics segment offers MassARRAY, a genetic analysis tool system, and related consumables, including chips, panels, and chemical reagent solutions used by clinical labs to analyze DNA samples for hereditary disease screenings, pharmacogenetics, oncology related applications, and toxicology research. The Biopharmaceutical Development segment provides automated systems, such as Gyrolab xPand and Gyrolab xPlore hardware and software, Gyrolab Bioaffy consumable microfluidic disks, Gyrolab kits and Rexxip buffers for protein analysis; and PurePep Symphony and Chorus instruments for peptide synthesis. Its Calibration Solutions segment offers quality control products to measure and calibrate critical parameters in applications, such as renal care, gas flow, environmental and process monitoring, and torque testing in pharmaceutical, laboratory, medical device, manufacturing, industrial, and environmental applications. This segment's products include continuous monitoring systems, data loggers, and torque testing systems under the DialyGuard, DryCal, DataTrace, and ViewPoint brands. Mesa Laboratories, Inc. was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Key Executives

  • Siddhartha Chandrakant Kadia
  • John V. Sakys
  • Brian David Archbold
  • Lyndsey Crennen

Current Ownership Distribution

  • Institutions90.6M (71.83%)
  • Mutual Funds35.0M (27.72%)
  • Insiders569,720 (0.45%)
  • Other0 (0.00%)